Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of Hemopure (HBOC-201) during brief coronary occlusion in the catheterization laboratory
2005-003638-17Phase 2Completed
- Sponsor
- Biopure
- Start
- Feb 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hemoglobin glutamer-250 in acute coronary syndrome (ACS) and coronary arteriosclerosis, sponsored by Biopure. Primary endpoints: Change in left ventricular relaxation indices and Change in sum of ST segment deviations. Started Feb 2006; status: completed.
02
Drugs
hemoglobin glutamer-250
03
Conditions
acute coronary syndrome (ACS)coronary arteriosclerosis
Beyond the preview
Go deeper on 2005-003638-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003638-17.